Moderate-to-severe Plaque Psoriasis Clinical Trial
Official title:
Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting: a Monocentric, Retrospective Study
This study was a one-arm, retrospective cohort study that observed clinical psoriasis patients who received secukinumab treatment in Indonesia from the 01 August 2017 until the 31 October 2020. Patients' data were obtained from the medical records of a dermatology clinic in Jakarta, Indonesia. The primary endpoints were set at Week 16, and secondary endpoints at Weeks 16 and 52. At each endpoint, the study assessed effectiveness by measuring the proportion of psoriasis patients receiving secukinumab who achieved Psoriasis Area and Severity Index (PASI) 75 (at Week 8) and PASI 90 (at Weeks 16 and 52).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04612699 -
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
|
Phase 2 | |
| Not yet recruiting |
NCT06258668 -
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
|
||
| Recruiting |
NCT06142357 -
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
|
||
| Recruiting |
NCT06182384 -
A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices
|
Phase 1 | |
| Recruiting |
NCT03710681 -
A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis
|
Phase 1 | |
| Not yet recruiting |
NCT04839016 -
Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis
|
Phase 3 |